Merit Financial Group’s Cytosorbents Corp CTSO Stock Holding History

Merit Financial Group’s Portfolio CTSO Stock Details CTSO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.72K	Hold	15,297	–	–	﹤0.01%	2356
2026 Q1	$8.66K	Hold	15,297	–	–	﹤0.01%	2108
2025 Q4	$9.78K	Hold	15,297	–	–	﹤0.01%	1952
2025 Q3	$14.3K	Hold	15,297	–	–	﹤0.01%	1789
2025 Q2	$19.6K	Buy	15,297 +214	+1%	+$215	﹤0.01%	1688
2025 Q1	$15.1K	Buy	15,083 +83	+0.6%	+$87	﹤0.01%	1392
2024 Q4	$13.7K	Hold	15,000	–	–	﹤0.01%	1148
2024 Q3	$22.5K	Buy	+15,000	New	+$16.4K	﹤0.01%	824

Other funds holding CTSO

KCFA

Key Client Fiduciary Advisors Fairfield, New Jersey $347M AUM 35.3% 1-Year Est. Return

SAM

Seelaus Asset Management Chatham, New Jersey $142M AUM 48.54% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Merit Financial Group's CTSO Position: Q2 2026 in Review

Merit Financial Group held its Cytosorbents Corp (CTSO) position steady in Q2 2026 at 15,297 shares worth $5.72K. The position accounts for ﹤0.01% of the portfolio, ranked #2356.

Merit Financial Group first reported a position in CTSO in Q3 2024 and has held it in 8 quarters since. The position peaked at $22.5K in Q3 2024. 4 funds tracked by Wall St. Rank hold CTSO as of Q2 2026.

Merit Financial Group held 15,297 shares of Cytosorbents Corp worth $5.72K as of Q2 2026.
Merit Financial Group left its Cytosorbents Corp share count unchanged in Q2 2026.
Cytosorbents Corp made up ﹤0.01% of Merit Financial Group's portfolio in Q2 2026, its #2356 holding.
Merit Financial Group first reported a position in Cytosorbents Corp in Q3 2024 and has held it in 8 quarters since.
Merit Financial Group's Cytosorbents Corp position peaked at $22.5K in Q3 2024.
4 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q2 2026.

Based on Merit Financial Group's 13F filing for Q2 2026, filed 17 Jul 2026.